Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that after 12 months of treatment with 5 mg of finasteride, patients with benign prostatic hyperplasia showed reduced prostate volume, DHT and PSA levels, and improved urinary flow rates and symptoms.

This study found that using 5α-reductase inhibitors during active surveillance for low-risk prostate cancer reduced prostate volume by 23% and was associated with a lower progression rate.

This study found that dutasteride effectively improved urinary symptoms, reduced acute urinary retention risk, and decreased prostate volume in men with moderate to severe BPH over two years.

This review summarizes existing studies on 5-alpha reductase inhibitors, noting their effectiveness in reducing prostate volume and cancer risk but highlighting an increased risk of higher grade prostate cancer.

This review examines recent advancements in analytical techniques used to quantify dutasteride, a medication for enlarged prostate, in various biological samples and its commercial forms, emphasizing methods such as HPTLC, GC-MS, and HPLC.

In this rat study, finasteride treatment significantly reduced body, testis, epididymis, and prostate weights and affected testicular histology, indicating potential negative impacts on testicular function.

This commentary reviews the post-Finasteride syndrome and argues that while the condition's validity is debated, comprehensive guidelines are needed to address related risks and treatment options; it reports no new clinical results.

Finasteride may decrease semen quality but not harm sperm production, and stopping the drug can improve semen quality; hyperprolactinemia can cause infertility but is treatable with medication.

The researchers reported that finasteride prevents further hair loss in males with androgenetic alopecia by promoting hair growth, which helps maintain scalp coverage, but it is not effective for females.

Finasteride slightly improves prostate symptoms but has minimal difference from placebo.

This review discusses the use of finasteride and alpha antagonists for symptomatic benign prostatic hypertrophy and suggests current studies are evaluating combination therapies as potential non-surgical alternatives.

More biopsy cores and MRI before biopsy can improve prostate cancer detection.

Combining medications is more effective for treating benign prostatic syndrome symptoms.

This review discusses the drug treatment of benign prostatic syndrome, highlighting the efficacy of combination therapies over monotherapies in patients at high risk for disease progression, but notes increased side effects and costs.

This article discusses the documented benefits of finasteride for managing benign prostatic hyperplasia, noting the need for monitoring due to its effects on serum PSA levels; it reports no adverse impact on prostate cancer detection.

This study reports an increase in the use of tamsulosin/finasteride for benign prostatic syndrome in Germany but highlights that reliable comparisons with monotherapies are lacking due to study design deficiencies.

This study found that finasteride improved urodynamic measures of obstruction in men with benign prostatic enlargement and lower urinary tract symptoms, with continued improvement over two years of treatment.

In this study, dual therapy with tamsulosin and solifenacin significantly improved urinary symptom severity and bladder capacity in BPH patients, but did not alter post-void residual urine volume. This supports using the combination therapy for managing LUTS, especially for storage-related symptoms, in clinical settings.

This consensus summary suggests that 5-alpha reductase inhibitors have clear benefits for benign prostatic hyperplasia, but their impact on prostate cancer prevention is still debated.

This review discusses 5-alpha reductase inhibitors, highlighting their long-term efficacy and tolerability in treating benign prostate hyperplasia, while also noting sexual dysfunction as a common adverse effect.

This study found that combining tamsulosin and finasteride significantly improved urinary symptoms and IPSS scores in elderly patients with benign prostatic hyperplasia compared to finasteride alone, with good safety profiles.

Dutasteride reduces DHT and improves BPH symptoms more effectively than finasteride.

This review discusses the role of finasteride preoperatively in reducing bleeding and complications during TURP and reports no new clinical results; the authors emphasize its potential benefits based on existing studies.

This case report describes two German shepherd dogs with prostatitis that showed favorable responses to treatment with finasteride, phenazopyridine, and enrofloxacin.

New treatments for male hypogonadism are effective and should be personalized.

This review reports that resveratrol could benefit the management of chronic illnesses such as diabetes and cardiovascular disease, but challenges with bioavailability and regulatory issues persist.

Higher CRP levels suggest chronic inflammation is linked to bladder-related urinary symptoms in men with enlarged prostates.

This study observed that men with frontal and moderate vertex baldness between ages 40 and 50 had a higher risk of aggressive prostate cancer, suggesting a potential link between baldness pattern and cancer risk.

This study found that patients with androgenetic alopecia frequently had higher PSA levels and more significant urinary symptoms, likely due to older age, though prostate weight did not differ.

This study reports that Abelson Interactor 1 (ABI1) regulates androgen receptor transcription in prostate cancer, identifying it as a potential target for new therapies addressing treatment resistance.